ESC Premium Access

Effect of sacubitril-valsartan in reducing physical frailty in patients with advanced heart failure in waiting list for heart transplantation

Congress Session

About the speaker

Doctor Giuditta Benincasa

University of Campania Luigi Vanvitell, Naples (Italy)
0 follower

9 more presentations in this session

Transcoronary transfer of Wharton's jelly mesenchymal pluripotent stem cells in patients with chronic ischaemic heart failure shows safety and unprecedented high-grade myocardial uptake

Speaker: Doctor A. Kozynacka (Cracow, PL)

Thumbnail

Use of sacubitril-valsartan in an extensive long term follow up cohort in real life

Speaker: Doctor A. Garcia Quintana (Palmas de Gran Canaria, Las, ES)

Thumbnail

Changes in glycated hemoglobin in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Thumbnail

Valsartan reduces level of soluble ST2 and left ventricle remodeling in patients with dual chamber pacemaker

Speaker: Mrs E. Radzik (Zabrze, PL)

Thumbnail

Eligible patients for the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk

Speaker: Doctor X. Chen (Gothenburg, SE)

Thumbnail

Access the full session

Poster Session 1 - Treatment of the chronic heart failure

Speakers: Doctor G. Benincasa, Doctor A. Kozynacka, Doctor A. Garcia Quintana, Mrs E. Radzik, Doctor X. Chen
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk